Company Profiles

driven by the PitchBook Platform

Agilis Biotherapeutics

Description

Developer of DNA based therapeutics designed to treat life-threatening or fatal rare diseases. The company's DNA based therapeutics uses the transformative approach based on delivering a corrected copy of a naturally occurring gene directly to targeted cells designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system.

2013

Founded

PRIVATE

Status

1-10

Employees

Series B

Latest Deal Type

$12.7M

Latest Deal Amount

$20.7M

Total Amount Raised

Description

Developer of DNA based therapeutics designed to treat life-threatening or fatal rare diseases. The company's DNA based therapeutics uses the transformative approach based on delivering a corrected copy of a naturally occurring gene directly to targeted cells designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system.

Website:

www.agilisbio.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Primary Office

Kendall Square, 245 First Street Suite 1800 Cambridge, MA 02142United States +1 (617) 444-8706
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Agilis Biotherapeutics's full profile, request a free trial.

Agilis Biotherapeutics Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Agilis Biotherapeutics Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Agilis Biotherapeutics Investors (5)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
BioMatrix PartnersVenture CapitalMinority000 0000000 0000
Gold Bench CapitalOtherMinority000 0000000 0000
Sands Capital VenturesVenture CapitalMinority000 0000000 0000
Third SecurityVenture CapitalMinority000 0000000 0000
WhiteRock Capital PartnersOtherMinority000 0000000 0000
BioMatrix Partners Venture Capital
Gold Bench Capital Other
Sands Capital Ventures Venture Capital
Third Security Venture Capital
WhiteRock Capital Partners Other

Agilis Biotherapeutics Executive Team (4)

NameTitleBoard
Seat
Contact
Info
Mark Pykett Ph.DChief Executive Officer, Board Member & President
Jodi Cook Ph.DVice President of Strategic Alliances & Chief Operating Officer
Kevin O'BrienVice President, Finance
Arthur Tzianabos Ph.DAdvisor
Mark Pykett Ph.D Chief Executive Officer, Board Member & President
Jodi Cook Ph.D Vice President of Strategic Alliances & Chief Operating Officer
Kevin O'Brien Vice President, Finance
Arthur Tzianabos Ph.D Advisor

Agilis Biotherapeutics Board Members (4)

NameRepresentingRoleSinceContact
Info
Adrian StecykGriffin SecuritiesCo-Founder, Chairman & Chief Executive Officer000 0000
Alexander SeaverSelfBoard Member000 0000
G.Houston HallSelfBoard Member000 0000
Mark Pykett Ph.DAgilis BiotherapeuticsChief Executive Officer, Board Member & President000 0000
Adrian Stecyk Co-Founder, Chairman & Chief Executive Officer Griffin Securities
Alexander Seaver Board Member Self
G.Houston Hall Board Member Self
Mark Pykett Ph.D Chief Executive Officer, Board Member & President Agilis Biotherapeutics
Request full access to PitchBook